<!DOCTYPE HTML>
<html lang="en">
<head>
	<meta charset="UTF-8">
	<title>VIKHI</title>
	<link rel="stylesheet" href="css/font-awesome/css/font-awesome.min.css" />

	<link rel="stylesheet" href="css/fonts/stylesheet.css" />
	<link rel="stylesheet" href="css/fonts/fonts.css" />
	<link rel="stylesheet" href="css/bootstrap/bootstrap.min.css" />
	<link rel="stylesheet" href="css/animat/animate.min.css" />
	<link rel="stylesheet" href="css/fancybox/jquery.fancybox.css" />
	<link rel="stylesheet" href="css/nivo-lightbox/nivo-lightbox.css" />
	<link rel="stylesheet" href="css/themes/default/default.css" />
	<link rel="stylesheet" href="css/owl-carousel/owl.carousel.css" />
	<link rel="stylesheet" href="css/owl-carousel/owl.theme.css" />
	<link rel="stylesheet" href="css/owl-carousel/owl.transitions.css">
	<link rel="stylesheet" href="css/style.css" />
	<link rel="stylesheet" href="css/responsive.css" />
	<link href="https://fonts.googleapis.com/css?family=Montserrat|Source+Sans+Pro" rel="stylesheet">
</head>
<body>

	<div class='preloader'><div class='loaded'>&nbsp;</div></div>

	<header id="home" class="header">
		<div class="main_menu_bg navbar-fixed-top">
			<div class="container">
				<div class="row">
					<div class="nave_menu">
					<nav class="navbar navbar-default">
					  <div class="container-fluid">
						<!-- Brand and toggle get grouped for better mobile display -->
						<div class="navbar-header">
						  <button type="button" class="navbar-toggle collapsed" data-toggle="collapse" data-target="#bs-example-navbar-collapse-1" aria-expanded="false">
						  </button>
						  <a class="navbar-brand" href="index.html">
							<div class="logo">
								<img src="images/vikhiLOGOsm.png" alt="" height="30"/>
							</div>
						  </a>
						</div>

						<!-- Collect the nav links, forms, and other content for toggling -->
						<div class="collapse navbar-collapse" id="bs-example-navbar-collapse-1">

						  <ul class="nav navbar-nav navbar-right">
							<li class="active"><a href="aspectos.html">1. General Aspects</a></li>
							<li><a href="recomendaciones.html">2. Recommendations</a></li>
							<li><a href="toxicidad00.html">3. Toxicities</a></li>
						  </ul>
						</div><!-- /.navbar-collapse -->
					  </div><!-- /.container-fluid -->
					</nav>
					</div>
				</div><!--Fin de row -->

			</div><!--Fin de container -->

		</div>
	</header> <!--Fin de header -->



	<section class="banner">
		<div class="container">
			<div class="row">
				<div class="main_banner_area text-center">
					<div class="col-md-12 col-sm-12">
						<div class="single_banner_text wow zoomIn" data-wow-duration="1s">
							<h2>General Aspects<br/>of Immunotherapy</h2>
							<br/>
							<div class="separator"></div>
							<h5>BASIC COURSE IN IMMUNOTHERAPY</h5>


						</div>
					</div>
				</div>
			</div>
		</div>
	</section><!-- Fin de Banner Section -->



	<section class="franja">
		<div class="overlay_franja">
			<div class="container">
				<div class="row">
					<div class="col-md-12 col-sm-12 col-xs-12">
						<div class="main_franja_content text-center wow fadeIn" data-wow-duration="2s">
							<h2>1<span class="negrita">.1</span> INTRODUCTION</h2>
						</div>
					</div>
				</div>
			</div>
		</div>
	</section>



	<section class="texto">
		<div class="container">
			<div class="row">
				<div class="parrafo wow zoomIn" data-wow-duration="0.5s">


					<p>Understanding the interaction between tumour cells and the immune system has led to the development of promising therapies aimed at the immune checkpoints, such as programmed death protein 1 (PD-1) and cytotoxic T-lymphocyte antigen-4 (CTLA-4), with clinical responses that were not insignificant. Recently, anti-CTLA-4 and anti-PD-1 monoclonal antibodies were approved for the treatment of metastatic melanoma and advanced non-small cell lung cancer.</p>
					<br/>
					<p>In addition to their efficacy profile, these targeted immunity agents also generate immunity-related adverse events (irAE). This new range of immune toxicities is little known by many professionals. Although severe irAEs are still rare (~10% of cases in monotherapy), some of them may become fatal if they are not managed and treated properly.</p>
					<br/>
					<div class="separator"></div>

				</div>
			</div>
		</div>
	</section>


	<section class="franja">
		<div class="overlay_franja">
			<div class="container">
				<div class="row">
					<div class="col-md-12 col-sm-12 col-xs-12">
						<div class="main_franja_content text-center wow fadeIn" data-wow-duration="2s">
							<h2>1<span class="negrita">.2</span> INTERACTION BETWEEN THE IMMUNE SYSTEM AND CANCER</h2>
						</div>
					</div>
				</div>
			</div>
		</div>
	</section>

	<section class="texto">
		<div class="container">
			<div class="row">
				<div class="parrafo wow zoomIn" data-wow-duration="0.5s">
					<p>The immune system is composed of the innate and adaptive system for the purpose of recognising and eliminating invading pathogens, including tumour cells.</p><br/>
				</div>
			</div>
		</div>
	</section>


	<section class="texto">
		<div class="container">
			<div class="row">
				<div class="main_texto_content text-center">

					<img src="images/inmunoSM.gif" alt="">

					<div class="col-md-6 col-sm-6 col-xs-12">
						<div class="single_texto wow fadeIn" data-wow-duration="2.8s">
							<div class="single_texto_img">
								<img src="images/dot.png" alt="" height="50px">
								<div class="single_texto_overlay text-center">
									<p>The innate immune system is the first protective barrier, which induces a rapid response, largely mediated by neutrophils, monocytes, macrophages, dendritic cells (DC), Natural-Killer (NK) cells, mast cells, T cells and various humoral components (including the complement system, interferons and interleukins).</p>
								</div>
							</div>
							<div class="single_texto_name">
								<h4>INNATE IMMUNE SYSTEM</h4>
							</div>
						</div>
					</div>
					<div class="col-md-6 col-sm-6 col-xs-12">
						<div class="single_texto wow fadeIn" data-wow-duration="2.8s">
							<div class="single_texto_img">
								<img src="images/dot.png" alt="" height="50px"/>
								<div class="single_texto_overlay text-center">
									<p>The adaptive immune system provides specific responses to antigens, conferring long-term protection, given their antigenic memory. Its main effector cells are T and B lymphocytes.</p>
								</div>
							</div>
							<div class="single_texto_name">
								<h4>ADAPTIVE IMMUNE SYSTEM</h4>
							</div>
						</div>
					</div>

				</div>
			</div>
		</div>
	</section>




	<section class="texto">
		<div class="container">
			<div class="row">
				<div class="parrafo wow zoomIn" data-wow-duration="0.5s">
					<p>The interaction between malignant cells and various components of immune response may inhibit or enhance tumour growth. CD8+ cytotoxic T lymphocytes (CTL), CD4+ helper type 1 (Th1), NK cells and activated macrophages (M1) have a tumour suppression function.</p><br/>
					<p>However, CD4+ Th2, CD4+ Th17 cells, myeloid cells with suppressive capacity (MDSCs), activated macrophages (M2) and CD4+ CD25+ Foxp3+ regulatory T cells (iTreg) protect tumour cells from attacks by the immune system. Therefore, the immune system is like a set of scales in continuous activity which must be balanced. When an imbalance occurs in favour of immune cells which enhance tumour progression, it requires effective immunotherapy treatment that would increase tumour immunity and inhibit the immune promoters of tumour progression.</p><br/>
					<p>The endogenous immune response in some types of cancer has a prognostic significance.</p>

					<br/>
					<div class="separator"></div>
				</div>
			</div>
		</div>
	</section>


	<section class="franja">
		<div class="overlay_franja">
			<div class="container">
				<div class="row">
					<div class="col-md-12 col-sm-12 col-xs-12">
						<div class="main_franja_content text-center wow fadeIn" data-wow-duration="2s">
							<h2>1<span class="negrita">.3</span> THE ROLE OF IMMUNE CHECKPOINT INHIBITORS</h2>
						</div>
					</div>
				</div>
			</div>
		</div>
	</section>


	<section class="texto">
		<div class="container">
			<div class="row">
				<div class="parrafo wow zoomIn" data-wow-duration="0.5s">
					<p>The immune checkpoints are regulatory signals that can mediate the anti-tumour immune response and self-tolerance. A good balance between inhibition/activation on the immune checkpoint is crucial for preventing autoimmunity phenomena in the patient and preventing side effects mediated by the immune system (immune-mediated adverse events).</p>
					<br/>
					<div class="separator"></div>
				</div>
			</div>
		</div>
	</section>



	<section class="testimonial">
		<div class="testimonial_overlay">
			<div class="container">
				<div class="row">
					<div class="parrafo text-center wow slideInDown" data-wow-duration="0.5s">
						<h2>There are different checkpoint inhibitors, such as:</h2>
					</div>
					<div class="main_testimonial text-center wow fadeIn" data-wow-duration="1s">
						<div class="single_testimonial">
							<div class="single_testimonial_img">
								<p>CLT type 4 antigens (CTLA-4)</p>
								<a href="">1</a>
							</div>
						</div>
						<div class="single_testimonial">
							<div class="single_testimonial_img">
								<p>programmed death type 1 (PD-1) receptor</p>
								<a href="">2</a>
							</div>
						</div>
						<div class="single_testimonial">
							<div class="single_testimonial_img">
								<p>lymphocyte-activation gene 3 (LAG-3)</p>
								<a href="">3</a>
							</div>
						</div>
						<div class="single_testimonial">
							<div class="single_testimonial_img">
								<p>T cell immunoglobulin and mucin protein-3 (Tim-3)</p>
								<a href="">4</a>
							</div>
						</div>
						<div class="single_testimonial">
							<div class="single_testimonial_img">
								<p>the B7-H3 complex (also called CD276)</p>
								<a href="">5</a>
							</div>
						</div>
					</div>
				</div>
			</div>
		</div>
	</section>


	<section class="texto">
		<div class="container">
			<div class="row">
				<div class="parrafo wow zoomIn" data-wow-duration="0.5s">
					<p>The main role of <span class="negrita">CTLA-4</span> is to absorb the initial activation of T cells by submitting antigens at the lymphoid tissue level. <span class="negrita">Ipilimumab</span> is a humanised immunoglobulin (IgG1) that is potentially inhibitory to CTLA-4, being the most advanced anti-CTLA-4 agent from a clinical point of view, which has shown benefits in terms of overall survival in metastatic melanoma.</p>
					<br/>
					<p>The second most studied receptor is PD-1, expressed in T-cells, mainly in the tumour microenvironment. It is able to limit T and B lymphocytes, NK cells and certain myeloid cells when they bind to their ligands: PLD-1, PLD-2.</p>
					<br/>
					<p>The first <span class="negrita">anti-PD-1</span> agent approved was <span class="negrita">Nivolumab</span>, a completely humanised anti-PD-1 IgG4 monoclonal antibody. It received accelerated approval from the FDA for metastatic/non-resectable melanoma, non-small cell lung cancer and metastatic renal cell cancer based on published efficacy data. <span class="negrita">Pembrolizumab</span> is the second therapeutic agent approved for the treatment of metastatic/advanced melanoma, non-small cell lung cancer and metastatic renal cell cancer.</p>
					<br/>
					<div class="separator"></div>

				</div>
			</div>
		</div>
	</section>




	<section class="counterUp">
		<div class="counter_overlay">
			<div class="container">
				<div class="row">
					<div class="main_counter_content text-center">
						<div class="col-md-12 col-sm-12 col-xs-12">


							<img src="images/diagnostico.png" alt="" height="40px"/> <br/><br/>
							<h2>CONCLUSIONS</h2>
							<br/><br/>

							<p>Understanding the evolutionary history of the tumour based on its changes and interactions with the immune system helps in the development of new clinical trials. Various therapeutic strategies are being evaluated: monotherapy treatments, treatments in combination with either radiotherapy, treatment vaccines, chemotherapy, or molecular targets, among others. A better understanding of the processes is guiding clinical development to strengthen anti-tumour immunity and tumour sensitivity to these treatments. One of the objectives is to avoid potential toxicities and to be able to manage possible autoimmune phenomena. In conclusion, it is crucial to be able to identify predictive biomarkers that may help us to select and identify patients who benefit from these treatments, to avoid potential side effects.</p>
						</div>
					</div>
				</div>
			</div>
		</div>
	</section>






	<footer id="footer" class="footer">
		<div class="container">
			<div class="row">
				<div class="main_footer text-center wow zoomIn" data-wow-duration="1s">
					<p class="centrado"><a href="https://www.e-oncologia.org/"><img src="images/LOGOeonco.png" alt="" height="22px"/></a></p>
				</div>
			</div>
		</div>
	</footer>

	<!-- STRAT SCROLL TO TOP -->

	<div class="scrollup">
		<a href="#"><img src="images/up.png" alt=""/></a>
	</div>






	<script type="text/javascript" src="js/jquery/jquery.js"></script>

	<script type="text/javascript" src="js/script.js"></script>

	<script type="text/javascript" src="js/bootstrap/bootstrap.min.js"></script>

	<script type="text/javascript" src="js/fancybox/jquery.fancybox.pack.js"></script>

	<script type="text/javascript" src="js/nivo-lightbox/nivo-lightbox.min.js"></script>

	<script type="text/javascript" src="js/owl-carousel/owl.carousel.min.js"></script>





	<script type="text/javascript" src="js/jquery-easing/jquery.easing.1.3.js"></script>
	<script type="text/javascript" src="js/wow/wow.min.js"></script>
	<!--<script type="text/javascript" src="js/counterup/counterup.min.js"></script>-->

	<!--<script src="http://cdnjs.cloudflare.com/ajax/libs/waypoints/2.0.3/waypoints.min.js"></script>-->
	<!--<script type="text/javascript" src="js/counterup/jquery.counterup.min.js"></script>-->


	<script type="text/javascript" src="js/isotop/isotope.min.js"></script>
	<script type="text/javascript" src="js/isotop/isotop.function.js"></script>

	<script type="text/javascript" src="js/masonry/masonry.min.js"></script>

	<script type="text/javascript" src="js/mixitup/jquery.mixitup.min.js"></script>
	<script type="text/javascript" src="js/masonry/masonry.pkgd.min.js"></script>
</body>
</html>
